Boule Diagnostics AB (SE:BOUL)
:BOUL
Want to see SE:BOUL full AI Analyst Report?
BOUL Stock Chart & Stats
kr3.22
kr0.07(2.22%)
―
--
Day’s Range― - ―
52-Week Rangekr3.09 - kr10.60
Previous CloseN/A
VolumeN/A
Average Volume (3M)39.59K
Market Cap
kr125.04M
Enterprise Valuekr332.43M
Total Cash (Recent Filing)kr18.50M
Total Debt (Recent Filing)kr222.00M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Jul 17, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding38,833,103
10 Day Avg. Volume77,284
30 Day Avg. Volume39,585
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)1.11
Price to Sales (P/S)0.38
P/FCF Ratio-69.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.82
Revenue Forecast (FY)kr499.00M
Bulls Say, Bears Say
Bulls Say
Recurring Consumables / Installed BaseBoule's business model generates recurring revenue from consumables and service tied to installed analyzers. This installed-base economics supports predictable, high-frequency demand for reagents and service over years, improving long-term revenue visibility and margin stability versus one-off instrument sales.
Structurally Solid Gross MarginsA gross margin near 44% indicates the company retains meaningful value on each test sold, enabling investment in R&D, service, and channels while supporting long-term profitability if fixed costs and overhead are managed. Durable gross margins cushion earnings through revenue variability.
Recent Positive Operating And Free Cash FlowRecent TTM positive operating and free cash flow demonstrate the company's ability to convert sales into cash in the near term, supporting working capital, service operations, and potential reinvestment. Consistent cash generation would reduce financing reliance and increase resilience.
Bears Say
Elevated LeverageDebt materially above equity (D/E ~1.5) reduces financial flexibility and raises refinancing and interest risks. If revenue or cash flow weakens, higher leverage increases default and cost-of-capital risk, constraining the company's ability to invest in product development or geographic expansion over the medium term.
Stalled Revenue And Net LossesDeclining TTM revenue and residual net losses indicate demand or pricing pressure and impaired bottom-line conversion. Continued revenue stagnation would limit scale benefits and strain margins, making it harder to restore sustainable net profitability without structural cost or product-market-share improvements.
Volatile Cash Conversion HistoryHistoric swings between positive and negative cash flow signal unpredictable conversion of earnings to cash, complicating capital planning. This volatility raises execution risk for long-term investments and heightens the need for conservative liquidity management or external financing during downturns.
Boule Diagnostics AB News
BOUL FAQ
What was Boule Diagnostics AB’s price range in the past 12 months?
Boule Diagnostics AB lowest stock price was kr3.09 and its highest was kr10.60 in the past 12 months.
What is Boule Diagnostics AB’s market cap?
Boule Diagnostics AB’s market cap is kr125.04M.
When is Boule Diagnostics AB’s upcoming earnings report date?
Boule Diagnostics AB’s upcoming earnings report date is Jul 17, 2026 which is in 38 days.
How were Boule Diagnostics AB’s earnings last quarter?
Boule Diagnostics AB released its earnings results on Apr 28, 2026. The company reported -kr0.38 earnings per share for the quarter, missing the consensus estimate of kr0.15 by -kr0.53.
Is Boule Diagnostics AB overvalued?
According to Wall Street analysts Boule Diagnostics AB’s price is currently Undervalued.
Does Boule Diagnostics AB pay dividends?
Boule Diagnostics AB does not currently pay dividends.
What is Boule Diagnostics AB’s EPS estimate?
Boule Diagnostics AB’s EPS estimate is 0.01.
How many shares outstanding does Boule Diagnostics AB have?
Boule Diagnostics AB has 38,833,103 shares outstanding.
What happened to Boule Diagnostics AB’s price movement after its last earnings report?
Boule Diagnostics AB reported an EPS of -kr0.38 in its last earnings report, missing expectations of kr0.15. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Boule Diagnostics AB?
Currently, no hedge funds are holding shares in SE:BOUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Boule Diagnostics AB
Boule Diagnostics AB (publ) operates as a diagnostic company specializing in the development, manufacturing, and commercialization of instruments and consumables designed for blood analysis. Its comprehensive product portfolio for human diagnostics includes a range of hematology analyzers, reagents, blood controls and calibrators, reagent rotors, and cleaning products, distributed under the Swelab, Medonic, and Quintus brand names. Furthermore, it provides veterinary hematology and clinical chemistry analyzer and diagnostic systems through its Exigo brand. Distribution is handled directly in Sweden and the United States, complemented by an international network of distributors. Boule serves a diverse client base encompassing hospitals, clinical laboratories, healthcare centers, veterinary clinics, and other diagnostic companies. The company maintains operational presences in Sweden, the United States, Mexico, and Russia. Established in 1956, Boule Diagnostics AB is headquartered in Spånga, Sweden.